Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on December 21, 2021. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cambridge, MA. The report specifically addresses a change in the Company's certifying accountant.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance and accounting disclosures.
Material Changes
- Appointment of New Auditor: On December 21, 2021, the Audit Committee appointed Marcum LLP as the independent registered public accounting firm to audit the consolidated financial statements for the fiscal year ending December 31, 2021.
- Resignation of Prior Auditor: PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (Copenhagen, Denmark) notified the Company on August 16, 2021, that they declined to stand for re-election for the 2021 fiscal year audit.
- Consultation History: The Company confirmed that no consultations occurred with Marcum LLP regarding accounting principles or audit opinions prior to their appointment, and no disagreements or reportable events were identified with the prior auditor.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure regarding the change in auditors. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the effective date of the transition from PricewaterhouseCoopers to Marcum LLP.
- Review the Company's subsequent filings (e.g., 10-K) to confirm the audit opinion issued by Marcum LLP for the fiscal year ended December 31, 2021.
- Confirm if the departure of the prior auditor was accompanied by any undisclosed disagreements or reportable events not mentioned in this 8-K.